Brand
Slate Run Pharmaceuticals
3 federal recalls on file. We monitor every CPSC, FDA, USDA, and NHTSA notice for Slate Run Pharmaceuticals and translate it into plain English — free weekly digest, optional same-day alerts.
- 2026-03-04FDA-DrugClass IIICheck Slate Run Eptifibatide Injection labeling
Labeling: Not Elsewhere Classified. The carton for Eptifibatide Injection 75 mg/100 mL states 75 mg/100 mL vial for weight-adjusted bolus dosing. The approved statement is 75 mg/100 mL vial for weight-adjusted infusion.
- 2025-03-26FDA-DrugClass IICinacalcet Hydrochloride Tablets 60 mg, 30-count bottle, Rx only, Distr. by: Slate Run Pharma., LLC, Columbus, Ohio 43215, Mfg. by: Piramal Pharma Limited, Madhya Pradesh, India, NDC 70436-008-04
CGMP deviations: The presence of nitrosamine impurity above the acceptable daily intake limits.
- 2025-03-26FDA-DrugClass IICinacalcet Hydrochloride Tablets 30 mg, 30-count bottle, Rx only, Distr. by: Slate Run Pharma., LLC, Columbus, Ohio 43215, Mfg. by: Piramal Pharma Limited, Madhya Pradesh, India, NDC 70436-007-04
CGMP deviations: The presence of nitrosamine impurity above the acceptable daily intake limits.
Get notified about new Slate Run Pharmaceuticals recalls
Free weekly digest. We email when a new federal recall affects Slate Run Pharmaceuticals or anything else in your household.
Get the Sunday BriefExplore other recall topics
By hazard
By state